Effects of two organotin(IV)(sulfonatophenyl)porphinates on MAPKs and on the growth of A375 human melanoma cells

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 593-599

  Costa, Maria Assunta ^a   Gulino, Letizia ^a   Pellerito, Lorenzo ^b   Fiore, Tiziana ^b   Pellerito, Claudia ^b   Barbieri, Giovanna ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

A375 melamoma cells; Cell growth; FAK; MAPKs; Meso tetra(4 sulfonatophenyl) porphinate

Indexed keywords

(DIBUTYLTIN) 2 MESOTETRA(4 SULFONATOPHENYL)PORPHINATE; (TRIBUTYLTIN) 4 MESOTETRA(4 SULFONATOPHENYL)PORPHINATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; ORGANOTIN COMPOUND; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INTERACTION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; WOUND HEALING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MELANOMA; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; MITOGEN-ACTIVATED PROTEIN KINASES; ORGANOTIN COMPOUNDS; PORPHYRINS;

EID: 64849101331     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000261     Document Type: Article

References (35)

1. Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature 445: 851-857, 2007.
2. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc 81: 500-507, 2006.
3. Pellerito A, Fiore T, Giuliani AM, Maggio F, Pellerito L and Mansueto C: Organometallic complexes with biological molecules: IX. Diorgano-and Triorgano-tin(IV)[meso-tetra(4sulfonatophenyl) porphinate] derivates: solid-state and solutionphase structural aspects and in vivo effects. Appl Organomet Chem 11: 707-719, 1997.
4. Tita SP and Perussi JR: The effect of porphyrins on normal and transformed mouse cell lines in the presence of visible light. Braz J Med Biol Res 34: 1331-1336, 2001.
5. Chwilkowska A, Saczko J, Modrzycka T, Marcinkowska A, Malarska A, Bielewicz J, Patalas D and Banas T: Uptake of photofrin II, a photosensitizer used in photodynamic therapy, by tumour cells in vitro. Acta Biochim Pol 50: 509-513, 2003.
6. Costa MA, Pellerito L, Izzo V, Fiore T, Pellerito C, Melis M, Musmeci MT and Barbieri G: Diorganotin(IV) and triorganotin(IV) complexes of meso-tetra(4-sulfonatophenil)porphine induce apoptosis in A375 human melanoma cells. Cancer Lett 238: 284-294, 2006.
7. Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997.
8. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J and Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160, 1994.
9. Han J, Lee JD, Bibbs L and Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811, 1994.
10. Engelberg D: Stress-activated protein kinases - tumor suppressors or tumor initiators? Semin Cancer Biol 14: 271-282, 2004.
11. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE and Herlyn M: Constitutive mitogenactivated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759, 2003.
12. Allen LF, Sebolt-Leopold J and Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30: 105-116, 2003.
13. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100, 2002.
14. Frisch SM, Vuori K, Ruoslahti E and Chan-Hui PY: Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793-799, 1996.
15. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH and Schaepfer DD: FAK integrates growth factor and integrin signals to promote cell migration. Nature Cell Biol 2: 249-256, 2000.
16. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET and Cange WG: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumor. Cancer Res 55: 2752-2755, 1995.
17. Kahana O, Micksche M, Witz IP and Yron I: The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene 21: 3969-3977, 2002.
18. Price JT and Thompson EW: Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 6: 217-233, 2002.
19. Tsuji T, Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, Mizushima H, Miyazaki K and Irimura T: Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin Exp Metastasis 19: 127-134, 2002.
20. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
21. Gervais FG, Thornberry NA, Ruffolo SC, Nicholson DW and Roy S: Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptitde. J Biol Chem 273: 17102-17108, 1998.
22. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K and Edwards BK: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88: 2398-2424, 2000.
23. Li G, Satyamoorthy K and Herlyn M: Dynamics of cell interactions and communications during melanoma development. Crit Rev Oral Biol Med 13: 62-70, 2002.
24. Xia M, Wang M, Tashiro S, Onodera S, Minami M and Ikejima T: Dracorhodin perchlorate induces A375-S2 cell apoptosis via accumulation of p53 and activation of caspases. Biol Pharm Bull 28: 226-232, 2005.
25. Mansouri A, Ridgway LD, Koarapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Millis GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
26. Cuadrado A, Garcia-Fernandez LF, Gonzales L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM and Munoz A: Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 278: 241-250, 2003.
27. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183, 2001.
28. Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
29. Xu L-H, Owens LV, Sturge GC, Yang X, Liu ET, Craven RJ and Cance WG: Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 7: 413-418, 1996.
30. Hungerford JE, Compton MT, Matter ML, Hoffstrom BG and Otey CA: Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 135: 1383-1390, 1996.
31. Rimm DL, Caca K, Hu G, Harrison FB and Fearon ER: Frequent nuclear/ cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154: 325-329, 1999.
32. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792, 1997.
33. Cadigan KM and Nusse R: Wnt signalling: a common theme in animal development. Genes Dev 11: 3286-3305, 1997.
34. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, Volpin D, Bressan GM and Piccolo S: Mapping Wnt/β-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 100: 3299-3304, 2003.
35. Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, Etoh T and Nakagawa H: Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun 288: 8-15, 2001.